About ManagedLab

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium dolemue launti totam aperiam, eaque ipsa quae abillo. Invente veriatis et quasi.

Kymera CEO Laurent Audoly Departs, Nelllo Mainolfi Named President

Posted by |2019-07-15T06:58:26-07:00July 15th, 2019|

Laurent Audoly, president and CEO of Kymera Therapeutics, is leaving “to pursue new entrepreneurial opportunities,” the Cambridge, MA, company announced Monday. Co-founder and chief scientific officer Nello Mainolfi has been appointed president, overseeing all company operations. He will also continue as CSO. Kymera said a search for a new CEO is underway. In other moves, […]

Athira Taps Alder Ex-Alder Bio Exec Litton as Chief Operating Officer

Posted by |2019-07-14T03:30:11-07:00July 12th, 2019|

Mark Litton has been appointed chief operating officer of Seattle-based Athira Pharma. Litton is the co-founder of Alder BioPharmaceuticals (NASDAQ: ALDR), and was chief business officer at that company until last July. Athira, previously known as M3 Biotechnology, is developing treatments for neurodegenerative disorders. The company is currently enrolling patients in a Phase 1b study […]

Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More

Posted by |2019-07-12T02:00:57-07:00July 12th, 2019|

The life science and healthcare worlds are vast. We often talk about impact in terms of millions of patients and billions of dollars. But these worlds can be small, too. It seems at times we’re never far removed from any one person, through their published papers, social media connections, friends, colleagues, or people they’ve mentored. […]

WI Startup Funding Hit Record in 2018 as VCs Cut Bigger Checks

Posted by |2019-07-10T13:30:15-07:00July 10th, 2019|

A record $300 million was invested in Wisconsin ventures last year, as maturing businesses pulled in larger funding rounds. But a continued decrease in the number of firms raising their first outside capital could signal trouble for the state’s pipeline of budding startups. Those are some of the key takeaways from the latest Wisconsin Portfolio, […]

After Amgen’s Spark, Revolution Med Nabs $100M to Push RAS Cancer Drugs

Posted by |2019-07-09T03:25:58-07:00July 9th, 2019|

In May, Amgen (NASDAQ: AMGN) revealed intriguing data from the first-ever human trial of a drug that targets tumors with a specific mutation to the gene KRAS, which occurs in about one-quarter of all cancers. Amgen showed 30 percent of lung cancer patients with the mutation saw their tumors shrink. Even though the data were […]

As Sangamo Touts Data, BioMarin Preps Hemophilia Gene Therapy For FDA

Posted by |2019-07-08T03:49:24-07:00July 8th, 2019|

[Updated 7/8/19, 9:22 am. See below.] Gene therapy for hemophilia is as close as it’s ever been to market. And the race to get there got more heated this past weekend at a medical meeting in Australia. At the International Society on Thrombosis and Haemostasis meeting in Melbourne, Sangamo Therapeutics (NASDAQ: SGMO) and partner Pfizer […]

Bio Roundup: Duchenne Race, Warren v. Gottlieb, A $599 Genome & More

Posted by |2019-07-08T03:30:08-07:00July 5th, 2019|

As we pause to celebrate the 4th of July, another birthday is top of mind: A third baby whose embryonic DNA was edited by Chinese scientist He Jiankui. As Xconomy reported in November, He hinted about a second pregnancy after his infamous revelation of twins altered with CRISPR gene editing tools. That second pregnancy—a third […]

BioAlta Taps Former Trillium Chief Medical Officer Eric Sievers as CMO

Posted by |2019-07-08T10:17:45-07:00July 2nd, 2019|

BioAtla, which is developing antibody drugs, has hired Eric Sievers as its chief medical officer. He was most recently CMO at Toronto’s Trillium Therapeutics (NASDAQ: TRIL), according to a news release from BioAtla. Prior, Sievers spent nine years at Seattle Genetics (NASDAQ: SGEN), where he was involved in the development and approval of brentuximab vedotin […]

San Diego Life Sciences Roundup: MEI Pharma, Turning Point, & More

Posted by |2019-07-02T03:30:09-07:00June 28th, 2019|

It was a relatively quiet week in the San Diego life sciences community, but local companies and organizations continue working away. Here’s a look at some recent developments, including companies moving their lead drug candidates into Phase 2 trials, new R&D partnerships, and a reminder to nominate your favorite young’un for a Biocom Catalyst award. […]

Amunix Taps Five Prime’s Irving for Chief Scientific Officer Role

Posted by |2019-06-27T08:51:30-07:00June 27th, 2019|

Bryan Irving has joined Amunix Pharmaceuticals as chief scientific officer, the same postion he held at Five Prime Therapeutics (NASDAQ: FPRX). Irving’s experience also includes posts at CytomX and Genentech. Mountain View, CA-based Amunix is developing protein-based therapies for cancer and other diseases.

Sequencing Firm Adaptive’s $300M IPO Comes With Pharma Ambitions

Posted by |2019-06-26T21:17:55-07:00June 26th, 2019|

If biotech’s historic bull run is losing steam, as some observers believe, this week is one hell of a final stampede. Adaptive Biotechnologies of Seattle just raised $300 million. BridgeBio Pharma of Palo Alto, CA, has topped it, raising $348.5 million. Both begin trading Thursday. The combined haul is a remarkable sum, more than 2 […]

Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits

Posted by |2019-06-26T01:55:13-07:00June 26th, 2019|

Despite the progress of gene therapy—a cutting edge medicine promising long-lasting effects from a single treatment—it remains a crude and limited tool. Startup Encoded Therapeutics has raised $104 million to join the race to expand gene therapy’s reach. The South San Francisco, CA, company has emerged from the startup accelerator of Illumina (NASDAQ: ILMN), and […]

Load More Posts